Advertisement

Esophagus

, Volume 16, Issue 4, pp 377–381 | Cite as

Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis

  • Tomohide Tanabe
  • Shintaro Hoshino
  • Noriyuki Kawami
  • Yoshimasa Hoshikawa
  • Yuriko Hanada
  • Nana Takenouchi
  • Osamu Goto
  • Mitsuru Kaise
  • Katsuhiko IwakiriEmail author
Original Article
  • 201 Downloads

Abstract

Background

To investigate the efficacy of long-term (52 weeks) maintenance therapy by 10-mg vonoprazan administration for proton pump inhibitor-resistant reflux esophagitis continued from the preceding study.

Methods

Sixteen patients with proton pump inhibitor-resistant reflux esophagitis (mean age 70.9 years, eight males) in whom endoscopic healing was achieved by 20-mg vonoprazan administration for 4 weeks and maintenance of remission was maintained by 10-mg vonoprazan administration for 8 weeks were enrolled. Endoscopy was performed at 52 weeks after the initiation of maintenance therapy with 10-mg vonoprazan to evaluate whether there was any recurrence of reflux esophagitis. Changes in the gastric mucosa were investigated at 52 weeks. Symptoms were assessed using the frequency scale for the symptoms of gastroesophageal reflux disease and the fast gastrin level at 8 and 52 weeks following the maintenance therapy.

Results

Endoscopic remission was maintained at 52 weeks in 15 (93.8%) of the 16 patients with proton pump inhibitor-resistant reflux esophagitis. One patient relapsed with grade C of reflux esophagitis. There were no significant differences in the symptom score at 8 and 52 weeks, nor the gastrin level at 8 and 52 weeks. There was no change in the stomach on endoscopy at 52 weeks.

Conclusion

Long-term maintenance therapy by 10-mg vonoprazan administration is very effective for proton pump inhibitor-resistant reflux esophagitis patients in whom endoscopic healing was maintained by 8 weeks maintenance therapy with 10-mg vonoprazan administration.

Keywords

PPI-resistant reflux esophagitis Vonoprazan Maintenance therapy 

Notes

Acknowledgements

The authors thank Ms. Satoko Nishimura for administrative assistance.

Compliance with ethical standards

Ethical Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Conflict of interest

Katsuhiko Iwakiri has received lecture fees from Takeda Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. The remaining authors declare that they have no conflicts of interest.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–48.CrossRefGoogle Scholar
  2. 2.
    Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–30.CrossRefGoogle Scholar
  3. 3.
    Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240–51.CrossRefGoogle Scholar
  4. 4.
    Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95:156–61.CrossRefGoogle Scholar
  5. 5.
    Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24:1550–61.CrossRefGoogle Scholar
  6. 6.
    Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.CrossRefGoogle Scholar
  7. 7.
    Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.CrossRefGoogle Scholar
  8. 8.
    Iwakiri K, Hoshino S, Kawami N. Mechanisms underlying excessive esophageal acid exposure in patients with gastroesophageal reflux disease. Esophagus. 2017;14:221–8.CrossRefGoogle Scholar
  9. 9.
    Iwakiri K. Treatment strategy for standard dose proton pump inhibitor-resistant reflux esophagitis. J Nippon Med Sch. 2017;84:209–14.CrossRefGoogle Scholar
  10. 10.
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172–80.CrossRefGoogle Scholar
  11. 11.
    Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–52.CrossRefGoogle Scholar
  12. 12.
    Röhss K, Wilder-Smith C, Nauclér E, et al. Esomeprazole 20 mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig. 2004;24:1–7.CrossRefGoogle Scholar
  13. 13.
    Norris V, Baisley K, Dunn K, et al. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2007;15(25):501–10.CrossRefGoogle Scholar
  14. 14.
    Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453–60.CrossRefGoogle Scholar
  15. 15.
    Yamasaki H, Kawaguchi N, Nonaka M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2016;14:1–8.Google Scholar
  16. 16.
    Hoshikawa Y, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus. 2019;16:201–6.CrossRefGoogle Scholar
  17. 17.
    Umezawa M, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis. Digestion. 2018;97:309–15.CrossRefGoogle Scholar
  18. 18.
    Jones MP, Sloan SS, Jovanovic B, et al. Impaired egress rather than increased access: an important independent predictor of erosive oesophagitis. Neurogastroenterol Motil. 2002;14:625–31.CrossRefGoogle Scholar
  19. 19.
    Hanada Y, Hoshino S, Hoshikawa Y, et al. Endoscopic diagnosis of hiatus hernia under deep inspiration is not consistent with esophageal manometric diagnosis. J Gastroenterol. 2018;53:712–7.CrossRefGoogle Scholar

Copyright information

© The Japan Esophageal Society and Springer 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyNippon Medical School, Graduate School of MedicineTokyoJapan

Personalised recommendations